FBXO28 Inhibitors

FBXO28 inhibitors represent a class of compounds that can disrupt the activity of F-box protein 28 (FBXO28), a member of the F-box protein family involved in the ubiquitin-proteasome pathway. FBXO28 mediates the ubiquitination of specific protein substrates, marking them for degradation by the proteasome. Thus, the inhibition of FBXO28 can affect protein turnover within the cell, leading to alterations in cellular processes where these proteins are involved.FBXO28 inhibitors can be classified into two broad categories based on their mechanism of action. The first category includes proteasome inhibitors such as MG132, bortezomib, epoxomicin, carfilzomib, lactacystin, and MLN2238 (ixazomib). These compounds prevent the degradation of ubiquitinated proteins, thereby indirectly influencing FBXO28 activity. By inhibiting the proteasome, these compounds cause an accumulation of ubiquitinated proteins, which may interfere with the normal function of FBXO28 and other F-box proteins. FBXO28 inhibitors can be classified into two broad categories based on their mechanism of action. The first category includes proteasome inhibitors such as MG132, bortezomib, epoxomicin, carfilzomib, lactacystin, and MLN2238 (ixazomib). These compounds prevent the degradation of ubiquitinated proteins, thereby indirectly influencing FBXO28 activity. By inhibiting the proteasome, these compounds cause an accumulation of ubiquitinated proteins, which may interfere with the normal function of FBXO28 and other F-box proteins.The second category includes inhibitors of deubiquitinating enzymes (DUBs), such as PR-619, ubiquitin aldehyde, WP1130 (degrasyn), and NSC632839. DUBs are enzymes that remove ubiquitin from proteins, reversing the effect of ubiquitination. By inhibiting DUBs, these compounds can affect the balance of protein ubiquitination and deubiquitination, potentially influencing FBXO28-related processes.